By Myles Starr
The narrow range of treatments available for multidrug-resistant (MDR) gram-negative infections—a leading cause of morbidity and mortality in the United States—poses a grave threat to patients in healthcare settings.
More than 2.8 million people become infected with antibiotic-resistant infections in the United States each year, and more than 35,000 people die as a result, according to the CDC (http://www.cdc.gov/DrugResistance/ Biggest-Threats.html).